A phase III study of STI571 versus interferon-alpha (IFN-alpha) combined with cytarabine (Ara-C) in patients with newly diagnosed, previously untreated, Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP).
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Imatinib (Primary) ; Cytarabine; Interferon alpha
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms IRIS
- Sponsors Novartis Pharmaceuticals Corporation
- 09 Mar 2017 11 year follow up results assessing long term safety and efficacy published in the New England Journal of Medicine.
- 06 Jun 2012 New source identified and integrated (German Clinical Trials Register DRKS00003841).
- 14 Sep 2010 Planned end date (January 2012) added as reported by ClinicalTrials.gov. record NCT00333840.